Clinical trials: Cutaneous Lupus Erythematosus
Cutaneous Lupus Erythematosus (CLE)
Prevalence and Clinical Severity of Cutaneous Lupus Erythematosus
The Cutaneous Lupus Erythematosus (CLE) database, established in 2006, is a multi-site database between the University of Pennsylvania and the University of Texas Southwestern (UTSW).
- Trial name
- NCT01510067
- Where
- 2 sites in United States
- Volunteers
- 700 people
- Sponsor
- University of Pennsylvania
Discoid Lupus Erythematosus
A Multicentre, Randomised, Double-blind, Positive-control Clinical Trial Evaluating Dihydroartemisinin Tablets for the Treatment of Discoid Lupus Erythematosus
This study is a multicentre, randomised, double-blind, double-dummy, phase II clinical trial with a positive-control group, designed to evaluate the efficacy and safety of dihydroartemisinin tablets in the treatment of discoid…
- Trial name
- NCT07557927
- Testing
- Dihydroartemisinin tablets, Hydroxychloroquine tablets
- Where
- 10 sites in China
- Volunteers
- 100 people
- Sponsor
- Kunming Pharmaceuticals, Inc.
Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE)
The Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of HC022 Injection in Subjects With SLE/CLE
The primary objective of this phase Ib study is to evaluate the safety and tolerability of multiple-ascending, subcutaneous (SC) doses of HC022 in SLE/CLE subjects.
- Trial name
- NCT07306585
- Testing
- HC022
- Where
- China
- Volunteers
- 32 people
- Sponsor
- HC Biopharma Inc.
Systemic Lupus Erythematosus
The WILLOW Study With M5049 in SLE and CLE (SCLE and/or DLE) (WILLOW)
The purpose of this Proof of Concept (PoC) and Dose-finding (DF) basket study is to evaluate the efficacy and safety of orally administered Enpatoran over 24 weeks in systemic lupus erythematosus (SLE) and cutaneous lupus…
- Trial name
- NCT05162586
- Testing
- Enpatoran low dose, Enpatoran medium dose, Enpatoran high dose
- Where
- 153 sites in United States, Argentina and 20 more
- Volunteers
- 456 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Idiopathic Inflammatory Myopathies, Diffuse Cutaneous Systemic Sclerosis
CARTIMMUNE: Study of Patients With Autoimmune Diseases Receiving KYV-101
The purpose of this study is to assess the safety, tolerability, and clinical activity of KYV 101 (a fully-human anti-CD19 CAR T-cell therapy) in adult subjects with B cell-driven autoimmune diseases.
- Conditions
- Idiopathic Inflammatory Myopathies, Diffuse Cutaneous Systemic Sclerosis, SLE Nephritis, ANCA Associated Vasculitis
- Trial name
- CARTIMMUNE (NCT06152172)
- Testing
- KYV-101, Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- David Porter
Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus
A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE)
The primary purpose of this study is to evaluate the efficacy, safety, and tolerability of IMVT-1402 in participants with Cutaneous Lupus Erythematosus.
- Trial name
- NCT06980805
- Testing
- IMVT-1402
- Where
- 86 sites in United States, Argentina and 11 more
- Volunteers
- 56 people
- Sponsor
- Immunovant Sciences GmbH
Systemic Lupus Erythematosus, Lupus Nephritis
A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases
CALiPSO-1 is a Phase 1, multi-centre, dose-confirmation study to evaluate the safety and efficacy of CNTY-101 in participants with refractory B cell-mediated autoimmune diseases including those with moderate to severe systemic…
- Conditions
- Systemic Lupus Erythematosus, Lupus Nephritis, Idiopathic Inflammatory Myopathies, Diffuse Cutaneous Systemic Sclerosis
- Trial name
- CALiPSO-1 (NCT06255028)
- Testing
- CNTY-101, IL-2, Lymphodepleting Chemotherapy
- Where
- 6 sites in United States
- Volunteers
- 6 people
- Sponsor
- Century Therapeutics, Inc.
Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus
A Long-Term Extension Study to Learn More About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus
In this study, researchers will learn more about a study drug called BIIB059 (litifilimab) in participants with cutaneous lupus erythematosus (CLE).
- Trial name
- AMETHYST LTE (NCT06044337)
- Testing
- BIIB059 (litifilimab)
- Where
- 104 sites in United States, Argentina and 23 more
- Volunteers
- 306 people
- Sponsor
- Biogen
Discoid Lupus Erythematosus, Systemic Lupus Erythematosus
Oral Tofacitinib in Adult Subjects With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE)
Evaluate the activity and safety of oral tofacitinib in adult patients with discoid lupus erythematosus with or without concurrent SLE.
- Trial name
- NCT03159936
- Testing
- Tofacitinib citrate
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Tufts Medical Center
Cutaneous Lupus Erythematosus
Deep Phenotyping of Cutaneous Lupus Erythematosus
Cutaneous lupus erythematosus (CLE) is an autoimmune disease of which the pathogenesis and pathophysiology are not fully understood.
- Trial name
- NCT06411106
- Testing
- IMIQUIMOD cream 50mg/g
- Where
- Netherlands
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Centre for Human Drug Research, Netherlands
Cutaneous Lupus Erythematosus
Interdisciplinary Study Group of Lupus Erythematosus (ISGLE)
Cutaneous lupus erythematosus (CLE) is a disease with a wide spectrum of clinical manifestations and a variable prognosis. The aim of this study is to create a standardized evaluation of the different subtypes of this disease in…
- Trial name
- NCT00420173
- Testing
- Laboratory analysis
- Where
- Germany
- Volunteers
- 45 people
- Sponsor
- European Society of Cutaneous Lupus Erythematosus e.V.
Cutaneous Lupus Erythematosus, Skin Lesion
Sunscreen RV 2457C in Photoinduced CLE
Lupus erythematosus (LE) is characterized by a large clinical spectrum, and sunligt is a well established factor in the induction and exacerbation of this disease.
- Conditions
- Cutaneous Lupus Erythematosus, Skin Lesion, Experimental Photoinduction, Protective Sunscreen
- Trial name
- NCT00470912
- Testing
- sunscreen RV 2547C
- Where
- Germany
- Volunteers
- 25 people
- Sponsor
- Heinrich-Heine University, Duesseldorf
Cutaneous Lupus Erythematosus (CLE), Systemic Lupus Erythematosus
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety of VENT-03 in Adult Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Lupus Erythematosus
The goal of this clinical trial is to learn if VENT-03 works to treat patients with cutaneous lupus erythematosus (CLE) who may or may not have systemic lupus erythematosus (SLE).
- Conditions
- Cutaneous Lupus Erythematosus (CLE), Systemic Lupus Erythematosus, SLE, SLE (Systemic Lupus)
- Trial name
- AERIS (NCT07260877)
- Testing
- VENT-03
- Where
- 34 sites in United States, Bulgaria and 6 more
- Volunteers
- 24 people
- Sponsor
- Ventus Therapeutics U.S., Inc.
Cutaneous Lupus Erythematosus (CLE)
A Study of Quinacrine in Participants With Cutaneous Lupus Erythematosus
The research study is being conducted to learn more about how patients with cutaneous lupus erythematosus (CLE) respond to the use of quinacrine.
- Trial name
- NCT07694336
- Testing
- Quinacrine Hydrochloride
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Victoria Werth
Cutaneous Lupus
Evaluation of Tofacitinib in Prevention of Photosensitivity in Lupus
This is a single-arm, multi-site, proof-of-concept study that will evaluate the treatment of 10 participants with cutaneous lupus erythematosus (CLE) with Tofacitinib.
- Trial name
- NCT05048238
- Testing
- Tofacitinib
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Cutaneous Lupus Erythematosus (CLE)
Evaluation of Lenalidomide (REVLIMID®) to Treat Subjects With Cutaneous Lupus Erythematosus (CLE)
This study is being conducted to evaluate the safety and effectiveness of lenalidomide (Revlimid®) in subjects with Cutaneous Lupus Erythematosus (CLE).
- Trial name
- NCT00633945
- Testing
- Lenalidomide
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Pennsylvania
Discoid Lupus Erythematosus
Comparing the Therapeutic Efficacy of Pimecrolimus Cream With Betamethasone Cream for Discoid Lupus Erythematosus
Discoid lupus erythematosus lesions are commonly treated with corticosteroids, but corticosteroids may induce side effects such as thinning of the skin or scarring.
- Trial name
- NCT00608673
- Testing
- Pimecrolimus 1% cream, betamethasone valerate 0.1% cream
- Where
- Iran
- Volunteers
- 10 people
- Sponsor
- Shahid Beheshti University of Medical Sciences
Discoid Lupus Erythematosus
Study of Daxdilimab (HZN-7734) in Participants With Moderate-to-Severe Primary Discoid Lupus Erythematosus
A Phase 2, double-blind, randomized, placebo-controlled parallel-group study to evaluate the efficacy and safety of daxdilimab in participants with moderate-to-severe active primary Discoid Lupus Erythematosus (DLE) refractory to…
- Trial name
- NCT05591222
- Testing
- Daxdilimab
- Where
- 68 sites in United States, Argentina and 9 more
- Volunteers
- 72 people
- Sponsor
- Amgen
Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE)
A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease
The purpose of this global, multicenter, Phase 3 study is to evaluate the efficacy and safety of enpatoran over 24 weeks in participants with active cutaneous manifestations of lupus erythematosus with or without systemic…
- Trial name
- ELOWEN-1 (NCT07332481)
- Testing
- Enpatoran, Standard of care (SoC)
- Where
- 60 sites in United States, Australia and 14 more
- Volunteers
- 202 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Cutaneous Lupus, Discoid Lupus
Safety Study of AMG 811 in Subjects With Discoid Lupus Erythematosus
This is a multi-center, randomized, double-blind, placebo-controlled, two-period, crossover study in which approximately 20 subjects with Discoid Lupus Erythematosus will be enrolled to receive AMG 811 and placebo in one of two…
- Conditions
- Cutaneous Lupus, Discoid Lupus, Lupus, Systemic Lupus Erythematosus
- Trial name
- NCT01164917
- Testing
- AMG811
- Where
- 8 sites in United States
- Volunteers
- 16 people
- Sponsor
- Amgen